BMS-986263 is a Antisense RNAi Oligonucleotide owned by Bristol-Myers Squibb, and is involved in 10 clinical trials, of which 9 were completed, and 1 is ongoing.
BMS-986263 (ND-L02-s0201) is a vitamin A–coupled liposomes which deliver siRNA against a collagen-specific chaperone heat shock protein 47 (HSP47). The drug candidate causes gene knockdown of a Hsp47 in fibrogenic cells. HSP47 siRNA suppresses collagen expression and macrophage infiltration, thereby preventing fibrosis. The drug candidate decreases levels of HSP47 in fibrotic diseases that limit the excessive assembly and intracellular processing of procollagen molecules, thereby reducing accumulation of collagens to delay the progression of fibrotic diseases.
The revenue for BMS-986263 is expected to reach a total of $68m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BMS-986263 NPV Report.
BMS-986263 (ND-L02-s0201) is under development for the treatment of non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis and cirrhosis secondary to non-alcoholic steatohepatitis (NASH) and hepatitis C. The drug candidate is administered through intravenous route. It is a vitamin A-coupled lipid nanoparticle (LNP) containing siRNA against heat shock protein 47 (HSP47). The drug candidate is based on siRNA technology.
Bristol-Myers Squibb Overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.
Quick View – BMS-986263
|Highest Development Stage|